8-K: Dermata Therapeutics Enters At-The-Market Offering Agreement to Sell Up to $1.16 Million in Common Stock

Dermata Therapeutics has entered into an agreement with H.C. Wainwright & Co., LLC to sell up to $1,157,761 of its common stock through an at-the-market offering.

Summary

• Dermata Therapeutics, Inc. has entered into an At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC.
• The company may sell shares of its common stock from time to time through the sales agent.
• The aggregate market value of shares eligible for sale is currently $1,157,761.
• The company will set parameters for the sale of shares, including the number of shares, time period, and minimum price.
• The sales agent may sell shares directly on the Nasdaq or in privately negotiated transactions with the company's prior written approval.
• The sales agent will use commercially reasonable efforts to sell shares based on the company's instructions.
• The company is not obligated to sell any shares and may suspend offers at any time.
• The sales agent will receive a 3.0% commission on the gross sales price of shares sold.
• The company will reimburse the sales agent for certain expenses, including up to $70,000 in aggregate, $5,000 per annual due diligence session, and $2,500 per quarterly due diligence session.
• The offering will terminate upon the sale of all shares or termination of the agreement.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. It outlines a standard financial transaction (ATM offering) which is a common way for companies to raise capital. While it does not indicate any major positive or negative developments, the potential for dilution is a slight negative.

Positives

• The ATM agreement provides Dermata Therapeutics with a flexible way to raise capital.
• The company retains control over the timing and pricing of share sales.
• The agreement allows for sales through various methods, including direct market sales and private negotiations.
• The company has the option to suspend offers at any time, providing flexibility in managing capital raising activities.

Negatives

• The company will incur expenses, including a 3.0% commission to the sales agent and reimbursement of certain expenses.
• The company is not guaranteed to sell all shares under the agreement.
• The offering could potentially dilute existing shareholders' ownership.

Risks

• The company may not be able to sell all the shares it intends to under the ATM agreement.
• Market conditions could impact the price at which shares are sold.
• The offering could lead to dilution of existing shareholders' equity.
• There is no guarantee that the company will be able to raise the full $1,157,761.

Future Outlook

The company intends to use the proceeds from the sale of shares for general corporate purposes, but the specific use of funds is not detailed in this document.

Management Comments

• The company will set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made.

Industry Context

At-the-market offerings are a common method for publicly traded companies, particularly smaller ones, to raise capital. This allows them to sell shares gradually into the market without significantly impacting the stock price.

Comparison to Industry Standards

• The 3.0% commission rate is within the typical range for at-the-market offerings.
• The expense reimbursement structure is also standard for these types of agreements.
• Many small cap biotech companies use ATM offerings to raise capital, similar to Dermata Therapeutics.
• Comparable companies that have used ATM offerings include XOMA Corporation and Agenus Inc.

Stakeholder Impact

• Shareholders may experience dilution of their ownership stake.
• The company will have additional capital to fund operations.
• The sales agent will earn commissions from the share sales.

Next Steps

• The company will begin selling shares through the sales agent based on the terms of the agreement.
• The company will file necessary prospectus supplements with the SEC.
• The company will monitor market conditions and adjust sales parameters as needed.

Key Dates

Keywords

At-The-Market Offering, Common Stock, Capital Raise, H.C. Wainwright, Sales Agent, Share Dilution, Dermata Therapeutics, Equity Financing